SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development. The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations. Under......

The board of Shanghai Fosun Pharmaceutical approved the spin-off and Hong Kong listing of its vaccine unit, aiming to bolster the business as biotechnology shares continue to outperform in the city's stock market. The board cleared the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical for a Hong Kong initial public offering (IPO) on Thursday, according to a late filing by Fosun Pharma, whose shares are listed in Shanghai and Hong Kong. The filing did not disclose the planned IPO......

Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and......

US-Pharmariesen verlieren Patentschutz im Marktwert von Milliarden Dollar. Chinesische Biotechs liefern Ersatz. Was heißt das für den globalen Pharma-Markt?...

Irina Zhou's five-year-old cat has gained about a kilogram every year for the past three years. She knows the extra weight puts her pet at risk of obesity-related diseases and could even shorten his life. “My parents just can't bear to see the cat go hungry,” the 29-year-old Zhou said. “If the weight starts to affect his health, I might consider trying weight-loss medicines for him.” The idea of using obesity drugs for pets drew public attention after Fosun Pharma's unit Yao Pharma signed a......

Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal Key Takeaways:    By Molly Wen It's becoming a familiar story: the Chinese drugs industry has signed another licensing deal with Big Pharma to fast track a weight-loss treatment. This time..... The post Lagging in the weight-loss market? Take Fosun's GLP-1 pill appeared first on Bamboo Works....

Shanghai Fosun Pharmaceutical Group Co. announced plans to acquire a controlling stake in a Chinese company that developed the country's first indigenous therapy for Alzheimer's disease only to wind up later suspending sales and production....

Boston, MA (www.aktiencheck.de) - Pfizer-Aktienanalyse von Leerink Partners: David Risinger, Analyst von Leerink Partners, stuft die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol: PFE) mit "market perform" ein. Pfizer habe am 9. Dezember 2025 bekannt gegeben, eine exklusive globale Kollaborations- und Lizenzvereinbarung mit YaoPharma, einer Tochtergesellschaft von Fosun Pharma, für YP05002 abgeschlossen zu haben - einen GLP-1RA-Small-Molecule-Kandidaten in Phase 1. [mehr]...

US pharmaceutical behemoth Pfizer has agreed to pay up to US$2.1 billion to Shanghai-based Fosun Pharma's unit Yao Pharma for an experimental oral obesity drug, underscoring the growing trend of Chinese drug makers selling early-stage assets to global multinationals. Under the licensing agreement, Yao Pharma would grant Pfizer an exclusive worldwide licence for the development, use, manufacturing and commercialisation of oral small-molecule drugs known as GLP-1 receptor agonists, including......

FOSUN PHARMA (02196.HK) signed a US$2.1 billion collaboration agreement with Pfizer (PFE.US) for its preclinical small molecule GLP-1 drug. Due to Pfizer's active involvement and long-term arrangement in the GLP-1 field, this collaboration gives YP05002 a leading position, CLSA released a research report saying. Compared to ......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Pfizer Inc. has entered into an exclusive global collaboration and licensing deal with a unit of Shanghai Fosun Pharmaceutical (Group) Co. for an early-stage weight-loss drug....

SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have......

FOSUN INTL (00656.HK) is participating in the China International Import Expo (CIIE) for eight years in a row. The company, alongside its overseas member enterprises and global partners, is showcasing innovative pharmaceuticals, high-end medical devices, and international collaboration achievements at the FOSUN PHARMA (02196.HK)......

Fangzhou and Fosun Pharma plan to build partnership in AI-powered chronic disease management, initially focused on psoriasis and other autoimmune condition...

Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";......

FOSUN PHARMA (02196.HK) announced that its operating revenue for the third quarter this year was RMB9.879 billion, down 5.46% YoY. The net profit attributable to shareholders was RMB821 million, up 4.52% YoY, with an EPS of RMB0.31.~AASTOCKS Financial NewsWebsite: www.aastocks.com...

Driven by accelerating healthcare demand, Fosun Health plans to target markets in South Asia, Southeast Asia and the Middle East to capitalise on their economic growth and fragmented health systems, according to chairman and CEO Frank Hu Hang. The subsidiary of Hong Kong-listed Shanghai Fosun Pharmaceutical (Group) operates 19 hospitals, clinics and third-party diagnostics centres in mainland China. Four of these are in Foshan, Guangzhou, Shenzhen and Zhuhai – cities that are part of the Greater......

Citi wrote in its research report that it had had a meeting with Guan Xiaohui, Co-Chairman of FOSUN PHARMA (02196.HK). Considering the company's attractive employee stock ownership plan targets, innovative pipeline valuation, and potential operational leverage effects, the broker raised its target price from HKD25 to HKD35.3......

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said. An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the......